Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being carried out to see which dose of AZD1305 is safe and effective in cardioverting atrial fibrillation into normal heart rhythm.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Clinical indication for cardioversion of Atrial Fibrillation, ie a correction of irregular heart rhythm to normal heart rhythm

• Current episode of Atrial Fibrillation (ie irregular heart rhythm) lasting up to 3 months at randomisation

• Adequate anticoagulation according to international guidelines (ACC/AHA/ESC, 2006) or national guidelines

Exclusion Criteria:

• Potassium level below 3.8 mmol/L measured in serum or plasma

• QTcF interval >440 ms